Exendin-4 Upregulates Adiponectin Level in Adipocytes via Sirt1/Foxo-1 Signaling Pathway
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) receptor plays an essential role in regulating glucose metabolism. GLP-1 receptor agonists have been widely used for treating diabetes and other insulin resistance-related diseases. However, mechanisms underlying the anti-diabetic effects of GLP-1 receptor agonists remain largely unknown. In this study, we investigated the effects of GLP-1 agonist exendin-4 on the expression of adiponectin, an insulin sensitizing hormone. We found that exendin-4 increased the expression and secretion of adiponectin both in vitro and in vivo. Our data showed that exendin-4 upregulated adiponectin expression at both mRNA and protein levels in adipocytes and adipose tissues. The effects of exendin-4 on adiponectin expression were dependent on the GLP-1 receptor. We further demonstrated important roles of Sirt1 and transcriptional factor Foxo-1 in mediating the function of exendin-4 in regulating adiponectin expression. Suppression of Sirt1 or Foxo-1 expression significantly impaired exendin-4-induced adiponectin expression. Consistently, exendin-4 up-regulated Sirt1 and Foxo-1 expression in vivo. Our work is the first study demonstrating the role of Sirt1/Foxo-1 in regulating the regulatory function of a GLP-1 receptor agonist in adiponectin expression both in vitro and in vivo. The results provide important information for the mechanism underlying the function of GLP-1R on improving insulin resistance and related diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This study demonstrated that modulating GLP-1R activity has the potential to improve both insulin secretion and action in T2D and that GLP-1 analogues may also be able to induce weight loss by augmenting adiponectin secretion, as well as inducing satiety.”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [271]
Experimental — accuracy not yet measuredIn the citing paper
“A recent study found that exenatide increased adiponectin secretion from adipose tissue in both in vivo and in vitro studies.271”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [271]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Diet-induced insulin resistance in mice lacking adiponectin/ACRP30
Maeda, N., Shimomura, I., Kishida, K., Nishizawa, H., Matsuda, M., Nagaretani, H., Furuyama, N., Kondo, H., Takahashi, M., Arita, Y., et al. (2002) · Nature Medicine · doi:10.1038/nm724 · Cited by 2,088
Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation
Fu, Y., Luo, N., Klein, R. L., & Garvey, W. T. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400373-jlr200 · Cited by 666
Ding, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557
Qiao, L., & Shao, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607215200 · Cited by 381
Plasma Adiponectin Levels in Overweight and Obese Asians
Yang, W., Lee, W., Funahashi, T., Tanaka, S., Matsuzawa, Y., Chao, C., Chen, C., Tai, T., & Chuang, L. (2002) · Obesity Research · doi:10.1038/oby.2002.150 · Cited by 220
Park, C. W., Kim, H. W., Ko, S. H., Lim, J. H., Ryu, G. R., Chung, H. W., Han, S. W., Shin, S. J., Bang, B. K., Breyer, M. D., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006070778 · Cited by 218
Weiss, R., Dufour, S., Groszmann, A., Petersen, K., Dziura, J., Taksali, S. E., Shulman, G., & Caprio, S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021711 · Cited by 193
Kim Chung, L. T., Hosaka, T., Yoshida, M., Harada, N., Sakaue, H., Sakai, T., & Nakaya, Y. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.10.015 · Cited by 158
Lee, J., Hong, S.-W., Chae, S. W., Kim, D. H., Choi, J. H., Bae, J. C., Park, S. E., Rhee, E.-J., Park, C.-Y., Oh, K.-W., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031394 · Cited by 157
Cited by
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Winiarska, A., Knysak, M., Nabrdalik, K., Gumprecht, J., & Stompór, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910822 · Cited by 191
Bednarz, K., Kowalczyk, K., Cwynar, M., Czapla, D., Czarkowski, W., Kmita, D., Nowak, A., & Madej, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084334 · Cited by 148
“adiponectin secretion in adipocytes [103,104].”
The Critical Role of SIRT1 in Parkinson’s Disease: Mechanism and Therapeutic Considerations
Li, X., Feng, Y., Wang, X.-X., Truong, D., & Wu, Y.-C. (2020) · Aging and disease · doi:10.14336/ad.2020.0216 · Cited by 134
Datta, R., Podolsky, M. J., & Atabai, K. (2018) · JCI Insight · doi:10.1172/jci.insight.122289 · Cited by 119
“Several other ECM components, such as secreted protein acidic and rich in cysteine (54, 55), biglycan (56), heparan sulfate proteoglycans (57, 58), aggrecan (59), entactin (60), laminin (60–62), and extendin-4 (63, 64), also have described roles in adipogenesis.”
BackgroundLe, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164674 · Cited by 66
“To this end, GLP-1 RAs, such as exendin-4, have been shown to increase adiponectin levels via Sirt1/FoxO1 signalling [147].”
BackgroundNovel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists
Mabilleau, G., Pereira, M., & Chenu, C. (2018) · Journal of Endocrinology · doi:10.1530/joe-17-0278 · Cited by 64
Packer, M. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.09.002 · Cited by 70
Simental‐Mendía, L. E., Sánchez‐García, A., Linden‐Torres, E., & Simental‐Mendía, M. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14855 · Cited by 59
“Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are a class of antidiabetic drugs that recently emerged for management of hyperglycaemia in type 2 diabetes; however, the exact mechanisms underlying the hypoglycaemic effects of GLP-1 RA are not fully understood yet.(6) A previous experimental study described that…”
BackgroundIm, D. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.09.001 · Cited by 69
“, 2010), and also enhances adiponectin secretion by adipocytes (Wang et al., 2017).”
BackgroundAdiponectin: The Potential Regulator and Therapeutic Target of Obesity and Alzheimer’s Disease
Kim, J. Y., Barua, S., Jeong, Y. J., & Lee, J. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176419 · Cited by 65
Quercetin activates the Sestrin2/AMPK/SIRT1 axis to improve amyotrophic lateral sclerosis
Jin, T., Zhang, Y., Botchway, B. O. A., Huang, M., Lu, Q., & Liu, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114515 · Cited by 64
The osteogenic effect of liraglutide involves enhanced mitochondrial biogenesis in osteoblasts
Pal, S., Maurya, S. K., Chattopadhyay, S., Pal China, S., Porwal, K., Kulkarni, C., Sanyal, S., Sinha, R. A., & Chattopadhyay, N. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.024 · Cited by 46
“Activation of GLP1R in the diabetic setting is known to increase serum adiponectin [35,36] but its effect on AdipoR1 expression remained unknown.”
BackgroundNguyen, T. T. N., Choi, H., & Jun, H.-S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00090 · Cited by 34
Huang, Y., Zhang, S., Fang, X., Qin, L., Fan, Y., Ding, D., Liu, X., & Xie, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193502 · Cited by 35
The Role of Adiponectin and ADIPOQ Variation in Metabolic Syndrome: A Narrative Review
Błażejewska, W., Dąbrowska, J., Michałowska, J., & Bogdański, P. (2025) · Genes · doi:10.3390/genes16060699 · Cited by 45
Role of FoxO1 in regulating autophagy in type 2 diabetes mellitus (Review)
Li, X., Wan, T., & Li, Y. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10139 · Cited by 39
“GLP-1 agonist exendin-4 induces adiponectin expression (69).”
BackgroundGlucagon-like peptide-1 receptor agonist stimulates mitochondrial bioenergetics in human adipocytes
Góralska, J., Śliwa, A., Gruca, A., Raźny, U., Chojnacka, M., Polus, A., Solnica, B., & Malczewska-Malec, M. (2017) · Acta Biochimica Polonica · doi:10.18388/abp.2017_1634 · Cited by 34
“Our results for SIRT1 and SIRT 3 expression are in line with a recent report that exendin-4 up-regulates adiponectin in adipocytes through the Sirt1/Foxo-1 signaling pathway (Wang et al., 2017).”
ResultNew Insights into Adipokines as Potential Biomarkers for Type-2 Diabetes Mellitus
Catalina, M. O., Redondo, P. C., Granados, M. P., Cantonero, C., Sánchez-Collado, J., Albarrán, L., & López, J. J. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867325666171205162248 · Cited by 32
Song, X., Sun, Y., Wang, Z., Su, Y., Wang, Y., & Wang, X. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.955113 · Cited by 28
Metabolic effects of antidiabetic drugs on adipocytes and adipokine expression
Yaribeygi, H., Simental‐Mendía, L. E., Barreto, G. E., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28420 · Cited by 29
Liraglutide protects palmitate-induced INS-1 cell injury by enhancing autophagy mediated via FoxO1
Li, X., He, S., Wan, T., & Li, Y. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11786 · Cited by 29
“Moreover, the GLP-1 receptor agonist exendin-4 upregulates adiponectin levels in adipocytes via FoxO1, both in vitro and in vivo (34).”
BackgroundZhao, Y.-F. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.956277 · Cited by 29
“GLP-1 and CCK upregulate adiponectin expression in adipocytes (33, 84, 85).”
BackgroundGioxari, A., Amerikanou, C., Valsamidou, E., Kleftaki, S.-A., Tzavara, C. K., Kalaitzopoulou, A., Stergiou, I., Smyrnioudis, I., & Kaliora, A. C. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106821 · Cited by 23
Thakkar, H., Vincent, V., Shukla, S., Sra, M., Kanga, U., Aggarwal, S., & Singh, A. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00662-3 · Cited by 23
Bakkar, N. Z., AlZaim, I., & EL‐Yazbi, A. F. (2022) · Clinical Science · doi:10.1042/cs20220404 · Cited by 20
Mechanism of Action and Risk Prediction of Adiponectin in Cardiovascular Diseases
Li, S., Han, X., Song, J., Dong, M., & Xie, T. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2908286 · Cited by 19
“This process may be related to the ability of GLP-1 agonists to upregulate adiponectin mRNA in adipocytes through silent information regulator sirtuin 1(Sirt1) and the transcription factor Foxo-1, thereby enhancing adiponectin expression [136].”
King, M. R., Anderson, N. J., Deciu, M., Guernsey, L. S., Cundiff, M., Hajizadeh, S., & Jolivalt, C. G. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24706 · Cited by 19
“Several studies have shown that Ex4 induced increased adiponectin levels, directly promotes adiponectin secretion in adipocytes and improves insulin sensitivity (Kim Chung et al., 2009; Li et al., 2008; Pastel et al., 2016; Wang et al., 2017).”
BackgroundBeyond Body Size: Adiponectin as a Key Player in Obesity-Driven Cancers
Capuozzo, M., Celotto, V., Landi, L., Ferrara, F., Sabbatino, F., Perri, F., Cascella, M., Granata, V., Santorsola, M., & Ottaiano, A. (2023) · Nutrition and Cancer · doi:10.1080/01635581.2023.2272343 · Cited by 13
“…interactions with vital signaling molecules like GSK-3 (Glycogen Synthase Kinase-3), FOXO (Forkhead Box O), and PTEN (Phosphatase and Tensin Homolog), thereby exerting significant effects on a wide array of cellular processes, such as cell differentiation, migration, and apoptosis (27,28).”
BackgroundAhmadi, S. S., Filipsson, K., Dimenäs, H., Isaksson, S. S., Imberg, H., Sjöberg, S., Ahrén, B., Dahlqvist, S., Gustafsson, T., Tuomilehto, J., et al. (2019) · Obesity Science & Practice · doi:10.1002/osp4.324 · Cited by 14
“Animal models have shown both liraglutide and other GLP-1-receptor agonists to be associated with increased adiponectin levels (25,26), while there are few data from clinical studies (27–29).”
BackgroundLin, L.-C., Lee, L.-C., Huang, C., Chen, C.-T., Song, J., Shiao, Y., & Liu, H. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.152946 · Cited by 13
Chen, L., Zhang, Y., Chen, H., Zhang, X., Liu, X., He, Z., Cong, P., Chen, Y., & Mo, D. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b00856 · Cited by 12
Coenzyme Q10 deficiency can be expected to compromise Sirt1 activity
DiNicolantonio, J. J., McCarty, M. F., & O’Keefe, J. H. (2022) · Open Heart · doi:10.1136/openhrt-2021-001927 · Cited by 13
Sathyanarayana, A. R., Lu, C., Liaw, C., Chang, C., Han, H.-Y., Green, B. D., Huang, W., Huang, C., He, W.-D., Lee, L., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23074052 · Cited by 11
Vedantham, S., Kluever, A.-K., & Deindl, E. (2018) · Cells · doi:10.3390/cells7100181 · Cited by 13
GLP-1R agonist therapy and vaccine response: Neglected implications
van Niekerk, G., Coelmont, L., Alpizar, Y. A., Kelchtermans, L., Broeckhoven, E., & Dallmeier, K. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.07.006 · Cited by 11
“Indeed, GLP-1 has been observed to enhance the expression of anti-inflammatory cytokines such as adiponectin in 3T3-L1 adipocytes via Sirt1/Foxo-1 signalling [39].”
Do anti-obesity medical treatments have a direct effect on adipose tissue?
Vergès, B. L. (2024) · Annales d Endocrinologie · doi:10.1016/j.ando.2024.05.021 · Cited by 10
Hung, M.-W., Wu, C.-W., Kokubu, D., Yoshida, S., & Miyazaki, H. (2019) · Food Science and Technology Research · doi:10.3136/fstr.25.817 · Cited by 9
“In fact, there are reports indicating that the activation of SIRT1 or AMPK raised adiponectin expression during preadipocyte differentiation (Li et al., 2011; Wang et al., 2017) whereas these two molecules also inhibited PPARγ activity (Jiang et al., 2012; Picard et al., 2004).”
BackgroundKhaleel, E. F., Badi, R. M., Satti, H. H., & Mostafa, D. G. (2020) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13288 · Cited by 11
Liraglutide stimulates the β-catenin signaling cascade in mouse epididymal fat tissue
Gu, J., Shao, W., Liu, D., Feng, J. N., Pang, J., & Jin, T. (2022) · Journal of Molecular Endocrinology · doi:10.1530/jme-22-0026 · Cited by 8
Liu, C., Yu, X., Huang, Y., Xu, L., Zhou, R., Wang, Y., & Wang, W. (2024) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70021 · Cited by 7
“However, it should be noted that in healthy individuals with lean body mass, changes in GLP-1 levels do not seem to cause corresponding changes in FGF21 levels [38].”
Tomasik, J., Rustogi, N., Larsen, J. R., Jakobsen, M. I., Svensson, C. K., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. S. R., Koyuncu, K., Schjerning, O., et al. (2020) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgaa044 · Cited by 6
“Adiponectin serum levels increased with liraglutide, which is in concordance with preclinical data 48 and data from a clinical study where adiponectin was increased in Chinese patients with T2D following treatment with liraglutide.”
The Role of Perivascular Fat in the Diagnosis and Prognosis of Atherosclerosis
Polkinghorne, M., West, H. W., & Antoniades, C. A. (2023) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2023.3.e1 · Cited by 4
Mahalingam, S., Kharbanda, K. K., Casey, C. A., & Rasineni, K. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1752204 · Cited by 3
“Furthermore, by improving overall insulin sensitivity, GLP-1RAs decrease the toxic influx of free fatty acids from adipose tissue to the liver, thereby mitigating hepatic lipotoxicity (Wang et al., 2017).”
Mesbah, M. M., Rashed, L. A., El-Boghdady, N. A., & Said, M. M. (2023) · Reports of Biochemistry and Molecular Biology · doi:10.61186/rbmb.12.1.42 · Cited by 5
Naimi, S. A., & Turnock, C. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4836442 · Cited by 2
GLP-1 receptor agonism in cardiovascular disease prevention
Saleh, H. (2025) · Asia-Pacific Journal of Pharmacotherapy & Toxicology · doi:10.32948/ajpt.2024.11.22 · Cited by 1
COMPARATIVE STUDY BETWEEN BERBERINE AND EXENDINE 4 ON ADULT MALE DIABETIC ALBINO RATS
Alla, A. G., Alla, A. G., & Haredy, H. H. (2017) · Al-Azhar Medical Journal · doi:10.12816/0038276
Escalada, J. (2020) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2020.7148/2020
Estrategia de lucha contra "Ceratitis Capitata w." en cítricos
Olmos, R. V. M. (2002) · Vida rural
Cherdchom, S., Sereemaspun, A., Rojanathanes, R., & Aramwit, P. (2017) · Chula Digiverse · doi:10.58837/chula.the.2017.367
Exploring the therapeutic potential of GLP-1 receptor agonists in pulmonary arterial hypertension
Aguado, B., Lacoste-Palasset, T., Ruffenach, G., Bauer, F., Savale, L., Humbert, M. J. C., Montani, D., & Antigny, F. (2025) · ERJ Open Research · doi:10.1183/23120541.01479-2025
“GLP-1RAs modulate adipokine profiles by reducing leptin and increasing adiponectin, an effect associated with improved metabolic and vascular outcomes in cardiometabolic disease [71].”
Thakkar, H., Vincent, V., Sukhla, S., Sra, M., Kanga, U., Aggarwal, S., & Singh, A. (2021) · Figshare · doi:10.6084/m9.figshare.14445018
Obesity and metabolic changes in neurodegenerative diseases
Sousa, D. P., Caramelo, B., Tsatsanis, C., Castelo-Branco, M. S., & Matafome, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33841-0.00025-7
Optimizing GLP-1 Receptor Agonist Use: Mechanisms, Clinical Applications, and Safety Profiles
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8391-3
Burmeister, M. A., Brown, S. A., Greer, J. J., Hoggatt, T. J., & Zumwalt, W. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1925534
Adipocytes as a Mechanistic Link Between Incretin-Based Therapies and Hair Loss
Gupta, A. K., Kaur, J., Piguet, V., & Mirmirani, P. (2026) · Biology · doi:10.3390/biology15181642
“In isolated adipocytes, adiponectin production following GLP-1RA treatment was variably affected [67,75,92], although many studies demonstrated an increase following treatment with exendin-4 [93,94] or liraglutide [77,78,88].”
Shoukry, H. S., Harbieh, I., Harbieh, M., Elbana, A. K., Fahmy, E. K., A, A. M. M., Esmaeel, S. E., Alruwaili, M. G., Rehman, A. G. A., Elshafey, S., et al. (2026) · Journal of Pioneering Medical Science · doi:10.47310/jpms2026150903
“Co-delivery with natural SIRT1 activators could amplify the deacetylation of NF-κ B, leading to a more profound suppression of the "cytokine storm" in systemic conditions like sepsis [9,16]”
Influential
Metadata
- Authors
- Wang, A., Li, T., An, P., Yan, W., Zheng, H., Wang, B., & Mu, Y.
- Affiliations
- Chinese PLA General Hospital (CN)
- Corresponding author
- Mu, Yiming
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-01-25
- Volume
- 12
- Issue
- 1
- Pages
- e0169469
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5266308
- OpenAlex
- W2582102037
- Cited by
- 58
- References
- 19
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 6 · 2023: 5 · 2022: 8 · 2021: 6 · 2020: 8 · 2019: 6 · 2018: 5 · 2017: 6
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81471026)
- The Chinese Diabetes Doctors Funds
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- exendin-4, adiponectin, GLP-1 receptor agonists, SIRT1, FOXO1, adipocytes, insulin resistance, glucose metabolism, adipose tissue, insulin sensitization
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Forkhead Box Protein O1, Exenatide, Adipose Tissue, Animals, Peptides, Venoms, Signal Transduction, Up-Regulation, Adipocytes, 3T3-L1 Cells, Mice, Adiponectin, Incretins, Sirtuin 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.